1. Home
  2. NGNE vs TCI Comparison

NGNE vs TCI Comparison

Compare NGNE & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$21.31

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo Transcontinental Realty Investors Inc.

TCI

Transcontinental Realty Investors Inc.

HOLD

Current Price

$48.00

Market Cap

380.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
TCI
Founded
2003
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
380.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
TCI
Price
$21.31
$48.00
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$38.50
N/A
AVG Volume (30 Days)
226.2K
1.6K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.87
EPS
N/A
0.65
Revenue
N/A
$48,675,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$68.06
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$25.50
52 Week High
$37.27
$48.00

Technical Indicators

Market Signals
Indicator
NGNE
TCI
Relative Strength Index (RSI) 44.24 64.55
Support Level $19.65 $43.01
Resistance Level $23.00 $45.00
Average True Range (ATR) 1.44 0.92
MACD 0.27 0.12
Stochastic Oscillator 50.79 100.00

Price Performance

Historical Comparison
NGNE
TCI

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: